Plain-English translation of NCT06563895 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new medication called can prevent a rare inherited condition called transthyretin amyloidosis from developing in people who carry the genetic mutation but are still healthy. About 587 people will take either or a placebo (inactive pill) twice daily to see if the medication can stop the disease before symptoms appear.
Currently, there is no way to prevent this inherited disease in people who carry the gene but haven't gotten sick yet. This trial aims to find out whether starting treatment early—before any symptoms show—can prevent the heart and nerve damage that usually happens later in life.
You likely qualify if…
You likely don't qualify if…
You would take the medication (or placebo) by mouth twice a day for the duration of the study. You'll have regular visits to your study doctor for heart imaging tests (including magnetic resonance imaging), blood work, and check-ins to monitor how you're doing. The trial is double-blind, meaning neither you nor your doctor will know whether you're receiving the active medication or placebo—this helps researchers get accurate results.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States